Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy - Pipeline Review, H1 2019, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline landscape.
Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as chronic relapsing polyneuropathy is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling and numbness of hands and feet.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 2, 3, 4 and 2 respectively.
Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development
Argenx SE
CSL Ltd
GeNeuro SA
Immupharma Plc
Momenta Pharmaceuticals Inc
Octapharma AG
Pfizer Inc
Takeda Pharmaceutical Co Ltd
Teijin Pharma Ltd
UCB SA
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Drug Profiles
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
forigerimod acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hyaluronidase (recombinant, human) + immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-254 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06755347 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rozanolixizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
temelimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Product Development Milestones
Featured News & Press Releases
Feb 19, 2019: Gliknik to receive $15 million milestone payment from Pfizer following clinical progress with PF-06755347, previously known as GL-2045
Jun 15, 2018: CSL Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from the Largest CIDP Study, the PATH Trial, at the 4th Congress of the European Academy of Neurology
Jun 14, 2018: ImmuPharma: Results of CIDP Pre-Clinical Data
Apr 20, 2018: CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting
Mar 16, 2018: FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Jan 26, 2018: CHMP Recommends Extension of Indications for Hizentra
Nov 09, 2017: Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Sep 14, 2017: CSL Behring Announces FDA Approval of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults
Jul 19, 2017: FDA Accepts CSL Behrings Supplemental Biologics License Application for Hizentra Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication
Jul 11, 2017: CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders
Mar 01, 2017: CSL Behring Announces Largest Ever CIDP Clinical Study Completed
Feb 14, 2017: FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen to Treat Chronic Inflammatory Demyelinating Polyneuropathy, a Rare Neurological Condition
Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy
Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Argenx SE, H1 2019
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by CSL Ltd, H1 2019
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, H1 2019
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Immupharma Plc, H1 2019
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Momenta Pharmaceuticals Inc, H1 2019
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Octapharma AG, H1 2019
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc, H1 2019
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Teijin Pharma Ltd, H1 2019
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by UCB SA, H1 2019
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, H1 2019
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products, H1 2019
List of Figures
Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019
